Articles tagged "Rejection"

2018 American Transplant Congress
Effect of Belatacept on Late Acute Rejection Episodes and Graft Loss in Young Adults between the Ages of 18-24 Years: Post-Hoc Analysis of BENEFIT Study
A. Moudgil.
Nephrology, Children National Health System, Washington, DC.
Background: Recent data suggests higher incidence of late acute rejection (LAR) in young adults (18-24 years of age) causing graft loss just like adolescents due…
2018 American Transplant Congress
mRNA Transcript Profiles of 14 Genes in Plasma Exosome Predict Risk for Antibody-Mediated Rejection (ABMR) of Renal Allografts
H. Zhang,¹ E. Huang,² C. Nast,³ J. Kahwaji,² A. Vo,² S. Jordan,² M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ³Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Previously we reported that mRNA transcript profiles of 4 genes (gp130, SH2D1B, TNFα and CCL4) in plasma exosome could predict the risk of ABMR,…
2018 American Transplant Congress
Elevated Skin Specific Non-HLA Antibodies Correlate with Acute Rejection Episodes in Clinical VCA
B. Kollar,¹ A. Uffing,² T. Win,¹ S. Tasigiorgos,¹ B. Pomahac,¹ F. Quintana,³ L. Riella.²
¹Division of Plastic Surgery, Brigham and Women's Hospital, Boston, MA; ²Transplantation Research Center, Brigham and Women's Hospital, Boston, MA; ³Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA.
Introduction: Vascularized composite allotransplantation (VCA) is unique by presence of the skin in the allografts. Due to the high immunogenicity of skin and the presence…
2018 American Transplant Congress
Unsupervised Analysis of the Alloimmune Response in a Novel Model of Vascularized Composite Allotransplantation
J. Harden, A. Sang, X. Qu, C. Esquivel, O. Martinez, S. Krams.
Department of Surgery/Division of Abdominal Transplantation, Stanford University, Stanford, CA.
Vascularized composite allografts consists of skin, muscle, bone, and other tissues, and is more immunogenic than solid-organ allografts. Our laboratory developed a murine model to…
2018 American Transplant Congress
IL-6 Inhibition with Tocilizumab to Promote Tregs and Control Renal Graft Inflammation: A Prospective Randomized Controlled Trial
S. Chandran, J. Leung, Z. Laszik, Q. Tang, C. Hu, M. Sarwal, F. Vincenti.
UCSF, San Francisco.
Background: IL-6, a proinflammatory cytokine & key regulator of Treg/Th17, is strongly associated with renal graft rejection. In theory, IL-6 blockade with tocilizumab (TCZ), a…
2018 American Transplant Congress
Non-Invasive Proteomics to Detect Biomarkers for Kidney Allograft Dysfunction
M. Watson,¹ M. Srivastava,³ D. Little,¹ O. Eidelman,³ R. Nee,¹ A. Bera,³ J. Karaian,³ D. Oliver,¹ H. Pollard,³ R. Jindal.²
¹Nephrology, USU-Walter Reed, Bethesda, MD; ²Surgery, USU-Walter Reed, Bethesda, MD; ³Anamtomy, Physiology and Genetics, USU-School of Medicine, Bethesda, MD.
Background: Non-invasive biomarkers are needed for monitoring patients to predict early acute rejection (AR). We hypothesized that protein biomarkers released from rejecting allograft tissues can…
2018 American Transplant Congress
Significance of Antibody-Mediated Vascular Rejection (AMVR) on Graft Survival: Correlation with Pure Antibody-Mediated Rejection (AMR)
B. Ozdemir,¹ F. Ozdemir,² A. Terzi,² G. Ozdemir,¹ A. Ok Atilgan,¹ E. Ayvazoglu Soy,³ A. Akdur,³ G. Moray,³ M. Haberal.³
¹Pathology, Baskent University, Ankara, Turkey; ²Nephrology, Baskent University, Ankara, Turkey; ³Transplantation, Baskent University, Ankara, Turkey.
Introduction: The importance of the endarteritis on graft survival in recipients with AMR is controversial. Thus we aimed to understand the prognostic value of the…
2018 American Transplant Congress
The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis
S. Wan,^1,2 T. Ying,^1,2 K. Wyburn,^1,2 D. Roberts,^3,4 M. Wyld,^1,2 S. Chadban.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia; ³Department of Renal Medicine, Canberra Hospital and Health Services, Canberra, Australia; ⁴Medical School, Australian National University, Canberra, Australia.
Introduction: Current treatment strategies for antibody-mediated rejection (AMR) in kidney transplantation are based on low quality data from a small number of controlled trials. Novel…
2018 American Transplant Congress
Rejection and Graft Loss in Patients with BK Viremia after Simultaneous Pancreas and Kidney Transplant
D. Keys, S. Riad, V. Vakil, S. Jackson, D. Berglund, A. Matas, R. Kandaswamy.
University of Minnesota, Minneapolis, MN.
Background: BK virus is a recognized cause of kidney allograft dysfunction. The treatment of BK is immunosuppression reduction. This reduction in patients with a simultaneous…
2018 American Transplant Congress
Targeting Histone Deacetylase in Renal Tubular Epithelial Cells Inhibits Amplification of TH1 Cell-Mediated Inflammation
S. Kang, Y. Kim, S. Seo.
Inje University, Busan, Korea.
Background: Objective: More studies are focusing on renal tubular epithelial cells (RTECs) as a new target to restore inflammatory environment as clarifying their immune regulatory…